M&A / Deals Aligos and Xiamen Amoytop sign deal for HBV therapy Pharmaceutical TechnologyAligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The innovators working to make in vivo cell therapy a realityNext: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
